The meteoric rise in Medicare’s reimbursement of specialty wound treatments is prompting a rare call to action from federal fraud and abuse watchdogs.
A report released Monday by the US Department of Health and Human Services Office of Inspector General found that Medicare Part B spending on skin substitutes—which are artificial or biological materials used to repair damaged skin—rose by over 600% since 2022. This rise in spending, however, was not seen in Medicare Advantage, even though both programs have similar demographics.
The OIG claims this rise is partly attributed to traditional Medicare’s fee-for-service payment system, which often pays providers ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.